Your session is about to expire
← Back to Search
Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3 for Gram-Negative Bacterial Infection (NOOR Trial)
NOOR Trial Summary
This trial will study how well ceftazidime-avibactam works and how safe it is in hospitalized infants and neonates.
- Gram-Negative Bacterial Infection
NOOR Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowNOOR Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.NOOR Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the FDA given its okay to use multiple doses of Ceftazidime-Avibactam for Cohorts 1-3?
"Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3 is currently sitting at a 2 on our safety scale. This is due to it being in Phase 2 trials which only have data supporting safety, and no data yet for efficacy."
How many people total have signed up to be a part of this experiment?
"Forty-eight individuals are required for this clinical trial, all of which must meet the pre-determined inclusion criteria. Those chosen to participate can do so from multiple locations, such as Rutgers Robert Wood Johnson Medical School in New Haven, Connecticut and Yale-New Haven Hospital in Cleveland, Ohio."
Have other researchers looked into this phenomenon before?
"There are 6 ongoing clinical trials for Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3. These trials are being conducted in 85 cities across 17 countries. The first trial for this medication was completed in 2020 and involved 48 patients. This study successfully completed Phase 2 drug approval and since then, 46 additional studies have been completed."
What infections does Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3 typically help cure?
"Often, neutropenia is most effectively treated with Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3. This treatment option can also be efficacious for gram negative bacteria, intraabdominal infections, and lower respiratory tract infection (lrti)."
How many research facilities are conducting this trial?
"As of now, there are 20 patients recruited for this clinical trial. The locations where the trial is taking place include Rutgers Robert Wood Johnson Medical School in New Haven, Yale-New Haven Hospital in Cleveland, University Hospitals Cleveland Medical Center in Jackson and 20 other locations."
Are young adults eligible for this experiment?
"This trial is only for patients who are less than 3 months old. There are 220 clinical trials specifically catering to this age group and 661 clinical trials for people over the age of 65."
Are there historical precedents for the current trial involving Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3?
"Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3 was initially studied in the year 2020 at Hsinchu Mackay Memorial Hospital. To date there are a total of 46 completed studies. There are presently 6 actively recruiting trials, with many of these studies running out of New Haven, Connecticut."
Might I be able to join this medical study?
"This study is recruiting 48 people with bacterial infections aged 0 Days and 88 Days. Most notable, patients should meet the following criteria: Cohort 1: Full term infants (gestational age ≥ 37 weeks) with chronological age >28 days to <3 months (<89 days) or pre-term infants with corrected age >28 days to <3 months (<89 days). A maximum of 3 pre-term corrected age infants may be enrolled in each part (A and B) of Cohort 1. Sites will be notified in writing if this limit is reached., Cohort 3: Pre-term neon"
What is the goal of this research project?
"The primary outcome of this study will be evaluated over a Part B: Day 1 until Late Follow-up Visit (up to a maximum study duration of 49 days). The primary outcome is to Part A: Ceftazidime and avibactam plasma concentrations by nominal sampling time using appropriate descriptive statistics, eg, number, mean, standard deviation (SD), minimum, median, maximum, geometric mean, and coefficient of variation. Secondary outcomes include Part A: Number of subjects discontinued due to adverse events (AEs) which is defined as Evaluate the safety and tolerability of a single intravenous dose of ceftaz"
Can new enrollees join this experiment at this time?
"The trial is recruiting patients, as evidenced by the listing on clinicaltrials.gov. This study was first posted on 1/15/2020, and has had several updates since then, with the most recent being on 10/4/2022."
Share this study with friends
Copy Link
Messenger